CRESCENT BIOPHARMA, INC. (CBIO)

Nasdaq Pharmaceutical Pharmaceutical Preparations SIC: 2834
D
Pipeline Grade

Financial Position (from SEC Filings)

$189.3M
Cash & Equivalents
$8.9M
Quarterly Burn Rate
64 mo
Est. Cash Runway
$478M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

No upcoming catalysts detected for this company.

Active Clinical Trials (1)

NCT #TitlePhaseStatusEnrollment
NCT07335497 CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors PHASE2 Recruiting 290

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for CBIO.

SEC EDGAR Filings

All SEC filings for CRESCENT BIOPHARMA, INC. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.